Phospho-CRK (Tyr221) Recombinant Antibody

$Western blot analysis of (1) K562 cell lysate treated with AP; (2) K562 cell lysate. Using Phospho-CRK (Tyr221) (bsm-61622R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n$

Western blot analysis of (1) K562 cell lysate treated with AP; (2) K562 cell lysate. Using Phospho-CRK (Tyr221) (bsm-61622R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n

Applications

WB
ICC/IF

Reactivity

Human

Overview
Catalog #	bsm-61622r
Product Name	Phospho-CRK (Tyr221) Recombinant Antibody
Applications	WB, ICC/IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human CRK around the phosphorylation site of Y221
Modification Site	Tyr221
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	1398
Swiss Prot	P46108
Subcellular location	Cytoplasm, Cell membrane
Synonyms	Adapter molecule crk; avian sarcoma virus CT10 (v-crk) oncogene homolog; CRK; CRKII; Proto-oncogene c-Crk.
Background	The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling.
Application Dilution
WB	1:300-5000
ICC/IF	1:50-100